Infusional CDE with rituximab for the treatment of human immunodeficiency virus-associated non-Hodgkin's lymphoma: preliminary results of a phase I/II study.
Tirelli U, Spina M, Jaeger U, Nigra E, Blanc PL, Liberati AM, Benci A, Sparano JA.
Tirelli U, et al. Among authors: sparano ja.
Recent Results Cancer Res. 2002;159:149-53. doi: 10.1007/978-3-642-56352-2_18.
Recent Results Cancer Res. 2002.
PMID: 11785839
Clinical Trial.
Infusional CDE (cyclophosphamide, doxorubicin, etoposide; iCDE) is one of the most effective chemotherapeutic regimen for human immunodeficiency virus (HIV)-associated non-Hodgkin's lymphoma (NHL), with a complete remission rate of 46% and a median overall survival of 8.2 months …
Infusional CDE (cyclophosphamide, doxorubicin, etoposide; iCDE) is one of the most effective chemotherapeutic regimen for human immunodefici …